Ni-Catalyzed C-H Functionalization in the Formation of a Complex Heterocycle: Synthesis of the Potent JAK2 Inhibitor BMS-911543.
暂无分享,去创建一个
Bin Zheng | Jun Li | Jacob Albrecht | Michael Schmidt | Martin D. Eastgate | Kristy Tran | R. J. Fox | D. Skliar | O. Soltani | Jun Li | Omid Soltani | Martin D Eastgate | J. Albrecht | M. Fitzgerald | Carolyn S. Wei | B. Zheng | M. Schmidt | M. Mahoney | Kristy Tran | Keming Zhu | Monica A Fitzgerald | Carolyn Wei | Dimitri Skliar | Michelle Mahoney | Richard J Fox | Keming Zhu
[1] Francisco Cervantes,et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. , 2012, The New England journal of medicine.
[2] Bin Zheng,et al. Development of a Robust Process for the Preparation of High-Quality Dicyclopropylamine Hydrochloride , 2014 .
[3] H. H. Hodgson. The Sandmeyer reaction. , 1947, Chemical reviews.
[4] S. Buchwald,et al. Highly selective room-temperature copper-catalyzed C-N coupling reactions. , 2006, Journal of the American Chemical Society.
[5] Martin D. Eastgate,et al. Regioselective synthesis of 1,4-disubstituted imidazoles. , 2012, Organic & biomolecular chemistry.
[6] M. Scarsella,et al. A rapid and convenient synthesis of tetrakis(triphenylphosphine)palladium(O) and -platinum(O) complexes by phase-transfer catalysis , 1991 .
[7] The copper-catalyzed N-arylation of indoles. , 2002, Journal of the American Chemical Society.
[8] G. Cuny,et al. Synthesis of fused imidazoles, pyrroles, and indoles with a defined stereocenter α to nitrogen utilizing Mitsunobu alkylation followed by palladium-catalyzed cyclization. , 2011, The Journal of organic chemistry.
[9] Z. Estrov,et al. Chronic Myelogenous Leukemia: Biology and Therapy , 1999, Annals of Internal Medicine.
[10] Qi Gao,et al. The impact of palladium(II) reduction pathways on the structure and activity of palladium(0) catalysts. , 2013, Angewandte Chemie.
[11] K. Yakushijin,et al. Biomimetic synthesis of grossularines-1. , 2005, Angewandte Chemie.
[12] K. Nicholas,et al. Copper-Mediated Multiple C–H Functionalization of Aromatic N-Heterocycles: Bromoamination of Indoles and Pyrroles , 2012 .
[13] S. Buchwald,et al. An efficient copper-catalyzed coupling of aryl halides with imidazoles , 1999 .
[14] A. Tefferi,et al. Bone marrow immunohistochemical studies of angiogenic cytokines and their receptors in myelofibrosis with myeloid metaplasia. , 2003, Leukemia research.
[15] Y. Janin. Preparation and chemistry of 3/5-halogenopyrazoles. , 2012, Chemical reviews.
[16] G. Ege,et al. Aminopyrazoles. IV . Pyrazol-3- and 5-amines from 2,3-dihaloalkanenitriles or 3-chloroacrylonitriles and hydrazines† , 1982 .
[17] P. Wollan,et al. Population‐based incidence and survival figures in essential thrombocythemia and agnogenic myeloid metaplasia: An Olmsted county study, 1976–1995 , 1999, American journal of hematology.
[18] R. Rossi,et al. Selective Palladium‐Catalyzed Suzuki–Miyaura Reactions of Polyhalogenated Heteroarenes , 2012 .
[19] L. A. Carpino. 1-Hydroxy-7-azabenzotriazole. An efficient peptide coupling additive , 1993 .
[20] J. C. Sheehan,et al. Notes- A Convenient Synthesis of Water-Soluble Carbodiimides. , 1961 .
[21] Dirk Trauner,et al. Biosynthetic and biomimetic electrocyclizations. , 2005, Chemical reviews.
[22] P. Ross-Macdonald,et al. Characterization of BMS-911543, a functionally selective small-molecule inhibitor of JAK2 , 2012, Leukemia.
[23] W. Lewis,et al. A New Route to α-Carbolines Based on 6π-Electrocyclization of Indole-3-alkenyl Oximes , 2013, Organic letters.
[24] Kunihisa Yoshida,et al. Anodic cyanation of 1-methylimidazoles. , 1987 .
[25] Jesús A. Varela,et al. Construction of pyridine rings by metal-mediated [2 + 2 + 2] cycloaddition. , 2003, Chemical reviews.
[26] Martin D. Eastgate,et al. The Development of Scalable and Efficient Methods for the Preparation of Dicyclopropylamine HCl Salt , 2011 .
[27] F. Ullmann,et al. Ueber Synthesen in der Biphenylreihe , 1901 .
[28] David R. J. Hose,et al. N,N′-Carbonyldiimidazole-Mediated Amide Coupling: Significant Rate Enhancement Achieved by Acid Catalysis with Imidazole·HCl , 2009 .
[29] F. Ullmann,et al. Ueber die Phenylirung von Phenolen , 1905 .
[30] D. Gilliland,et al. A role for JAK2 mutations in myeloproliferative diseases. , 2008, Annual review of medicine.
[31] N. Hu,et al. Ligand-Accelerated Catalysis of the Ullmann Condensation: Application to Hole Conducting Triarylamines , 1999 .
[32] P. Campbell,et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders , 2005, The Lancet.
[33] S. Buchwald,et al. A general and efficient copper catalyst for the amidation of aryl halides. , 2002, Journal of the American Chemical Society.
[34] G. Ege,et al. Aminopyrazoles. V. Structure assignment of 1H-pyrazol-3-and 5-amines by means of the 1H NMR δ(4-H)-values of their exo-N-toluenesulfonyl derivatives† , 1984 .
[35] Iram Goldberg. Ueber Phenylirungen bei Gegenwart von Kupfer als Katalysator , 1906 .
[36] T. Ishikawa,et al. 2-Chloro-1,3-dimethylimidazolinium Chloride. 1. A Powerful Dehydrating Equivalent to DCC , 1999 .
[37] H. Bregman,et al. An unusual dehalogenation in the Suzuki coupling of 4-bromopyrrole-2-carboxylates , 2003 .
[38] A. Pardanani. JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials , 2008, Leukemia.
[39] L. Melton,et al. Trends in the incidence of polycythemia vera among olmsted county, Minnesota residents, 1935–1989 , 1994, American journal of hematology.
[40] F. Ullmann. Ueber eine neue Bildungsweise von Diphenylaminderivaten , 1903 .
[41] De novo synthesis of substituted pyridines , 2004 .
[42] J. Kochi. The Mechanism of the Sandmeyer and Meerwein Reactions , 1957 .
[43] M. Burke,et al. A general solution for unstable boronic acids: slow-release cross-coupling from air-stable MIDA boronates. , 2009, Journal of the American Chemical Society.
[44] J. Ho,et al. Novel, potent non-covalent thrombin inhibitors incorporating p(3)-lactam scaffolds. , 2002, Bioorganic & medicinal chemistry letters.
[45] C. Bloomfield,et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. , 2009, Blood.